EP Patent

EP3672581A1 — Amantadine compositions, preparations thereof, and methods of use

Assigned to Adamas Pharma LLC · Expires 2020-07-01 · 6y expired

What this patent protects

The invention relates to pharmaceutical compositions for the oral route comprising amantadine or a corresponding pharmaceutically acceptable salt, as well as a pharmaceutically acceptable excipient, which contain a low level of organic solvent. The invention also relates to metho…

USPTO Abstract

The invention relates to pharmaceutical compositions for the oral route comprising amantadine or a corresponding pharmaceutically acceptable salt, as well as a pharmaceutically acceptable excipient, which contain a low level of organic solvent. The invention also relates to methods of orally administering to a subject a composition comprising amantadine, or a corresponding pharmaceutically acceptable salt, which exhibits fewer gastrointestinal side effects or sleep disturbances. The invention further relates to sustained release compositions for the oral route comprising amantadine, or a pharmaceutically acceptable salt thereof, which are suitable for a single daily administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP3672581A1
Jurisdiction
EP
Classification
Expires
2020-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Adamas Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.